Potent Lipoglycopeptide Antibiotics Against C. Difficile

针对艰难梭菌的强效脂糖肽抗生素

• 批准号: nhmrc : 1063214
• 负责人: Prof Matthew Cooper
• 金额: $ 50.04万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/potent-lipoglycopeptide-antibiotics-c-difficile/455049
• 关键词: Potent; Lipoglycopeptide; Antibiotics; Against; C.

In some people C. difficile bacteria naturally reside in the gut. Other people accidentally ingest spores of the bacteria while they are patients in a hospital or nursing home. Sometimes, broad-spectrum antibiotics used to treat an infection also kill healthy gut bacteria. The gut then becomes overrun with C. difficile, causing diarrhoea and pain, and sometimes death. We will investigate the use of a new potent antibiotic, vancapticin, to kill C. difficle and prevent relapse of infection.

在一些人C。艰难梭菌自然存在于肠道中。其他人在医院或疗养院的病人中意外摄入了细菌孢子。有时，用于治疗感染的广谱抗生素也会杀死健康的肠道细菌。然后，肠道中的C。艰难，引起腹泻和疼痛，有时甚至死亡。我们将研究使用一种新的有效抗生素，vancapticin，杀死C。并防止感染复发。